Pfizer Inc.: Working together for a healthier world®At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. To learn more, please visit us at www.pfizer.com. DISCLOSURE NOTICE: The information contained in this release is as of July 15, 2013. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information about XELJANZ (tofacitinib citrate), including its potential benefits, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, whether we will be able to address the CHMP’s concerns to its satisfaction regarding the Marketing Authorization Application for XELJANZ for the treatment of adults with moderate-to-severe rheumatoid arthritis (the proposed indication) and receive a positive opinion from the CHMP for the proposed indication; whether and when the European Commission and regulatory authorities in other jurisdictions will approve applications that have been or may be submitted for the proposed indication, as well as their decisions regarding labeling and other matters that could affect its availability or commercial potential; uncertainties regarding the commercial success of the proposed indication; and competitive developments.